$8.57
2.11% yesterday
Nasdaq, Feb 28, 04:45 pm CET
ISIN
US6821431029
Symbol
OMER
Sector
Industry

Omeros Corporation Stock price

$8.75
-0.25 2.72% 1M
+4.62 111.86% 6M
-1.13 11.44% YTD
+4.20 92.31% 1Y
+1.55 21.53% 3Y
-3.98 31.26% 5Y
-12.18 58.19% 10Y
Nasdaq, Closing price Wed, Feb 26 2025
+0.30 3.55%
ISIN
US6821431029
Symbol
OMER
Sector
Industry

Key metrics

Market capitalization $493.73m
Enterprise Value $804.01m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio negative
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-173.36m
Free Cash Flow (TTM) Free Cash Flow $-154.91m
Cash position $123.16m
EPS (TTM) EPS $-2.30
P/E forward negative
Short interest 17.06%
Show more

Is Omeros Corporation a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,809 stocks worldwide.

Omeros Corporation Stock Analysis

Unlock Scores for Free

Analyst Opinions

4 Analysts have issued a Omeros Corporation forecast:

2x Buy
50%
2x Hold
50%

Analyst Opinions

4 Analysts have issued a Omeros Corporation forecast:

Buy
50%
Hold
50%

Financial data from Omeros Corporation

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
- -
-
100%
- Direct Costs 0.85 0.85
0% 0%
-
-0.85 -0.85
0% 0%
-
- Selling and Administrative Expenses 47 47
7% 7%
-
- Research and Development Expense 124 124
11% 11%
-
-173 -173
5% 5%
-
- Depreciation and Amortization 0.85 0.85
0% 0%
-
EBIT (Operating Income) EBIT -173 -173
5% 5%
-
Net Profit -135 -135
773% 773%
-

In millions USD.

Don't miss a Thing! We will send you all news about Omeros Corporation directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Omeros Corporation Stock News

Positive
Seeking Alpha
4 days ago
Omeros Corporation's stock rebounded after successful data analysis for narsoplimab, showing 68% lower death risk in HSCT-TMA patients compared to historical controls. FDA requested new statistical analysis for narsoplimab's BLA resubmission, which proved successful, leading to a potential approval by late 2025. Financial risks include limited cash runway and potential market constraints due to...
Neutral
Business Wire
8 days ago
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced statistical analysis results related to the expanded access program (EAP) for narsoplimab, Omeros' first-in-class monoclonal antibody inhibiting the lectin pathway of complement, in the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA), a life-threatening complication in both...
Neutral
Business Wire
14 days ago
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced the availability on its website of materials accompanying two presentations given at the 2025 Tandem Meetings – the Transplantation & Cellular Therapy Meetings of the American Society for Transplantation and Cellular Therapy and the Center for International Blood and Marrow Transplant Research. The following materials a...
More Omeros Corporation News

Company Profile

Omeros Corp. operates as a biopharmaceutical company. The firm engages in the discovery, development, and commercializes of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Head office United States
CEO Gregory Demopulos
Employees 198
Founded 1994
Website www.omeros.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today